11-Mar-2025 7:00 AM CST - Business Wire Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update. 2025 promises to be an exciting year for Astria, and we are building on the momentum from a successful 2024 with the initiation of two important clinical trials, said Jill C. Milne, Ph.D., C
25-Feb-2025 7:00 AM CST - Business Wire Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming TD Cowen 45th Annual Health Care Conference on Tuesday, March 4th at 9:50am ET in Boston, MA. A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/cowen177/atxs
4-Feb-2025 7:00 AM CST - Business Wire Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11th at 10:40am ET. A webcast of the presentation can be accessed at the following link: https://wsw.com/webcas
13-Nov-2024 3:10 PM CST - Business Wire Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. We had another strong quarter of execution for both navenibart and STAR-0310, said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. We are excited about the opportunity for navenibar
13-Nov-2024 7:00 AM CST - Business Wire Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies London Healthcare Conference on Wednesday, November 20th at 12:00pm GMT in London, UK. A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jeff315/at
11-Mar-2025 7:00 AM CST - Business Wire Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a corporate update. 2025 promises to be an exciting year for Astria, and we are building on the momentum from a successful 2024 with the initiation of two important clinical trials, said Jill C. Milne, Ph.D., C
25-Feb-2025 7:00 AM CST - Business Wire Astria Therapeutics to Present at Upcoming TD Cowen 45th Annual Health Care Conference Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming TD Cowen 45th Annual Health Care Conference on Tuesday, March 4th at 9:50am ET in Boston, MA. A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/cowen177/atxs
4-Feb-2025 7:00 AM CST - Business Wire Astria Therapeutics to Present at Upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on Tuesday, February 11th at 10:40am ET. A webcast of the presentation can be accessed at the following link: https://wsw.com/webcas
13-Nov-2024 3:10 PM CST - Business Wire Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. We had another strong quarter of execution for both navenibart and STAR-0310, said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. We are excited about the opportunity for navenibar
13-Nov-2024 7:00 AM CST - Business Wire Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies London Healthcare Conference on Wednesday, November 20th at 12:00pm GMT in London, UK. A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jeff315/at
